Business
Assembly Biosciences is a development-stage biopharma company with no approved products in the local filing text and revenue tied mainly to Gilead-related collaboration rows.
Assembly Biosciences revenue rose to $72.3M from Gilead-linked rows, losses narrowed, and FCF stayed negative at -$41.2M.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage antiviral biopharmaNote
- Revenue — Revenue rose 153.5%OK
- Losses — Net loss narrowed to $6.1MOK
- Cash — FCF was -$41.2MWatch
- Balance sheet — Equity rose to $206.8MOK
- Insiders — 1 buy / 2 sells; buy value zeroNote
- Accounting — Altman-Z distressWatch
Where the revenue comes from
Fiscal 2025, as ASSEMBLY BIOSCIENCES, INC. reports it. History and quarterly detail are in the app.
- Related Party$72.3M
- Gilead Sciences Incorporated$72.3M
Leadership changes
From ASSEMBLY BIOSCIENCES, INC.'s own filings, the day they're filed.
- Jeanette M. Bjorkquist · principal accounting officer · appointmenteff. 2025-06-05
- Robert D. Cook II · President · appointmenteff. 2024-03-13
- Tomas Cihlar · President · appointmenteff. 2023-12-07
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-06-05
- 8-K · Company announcement2026-05-26
- 8-K · Company announcement2026-05-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ASSEMBLY BIOSCIENCES, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.